Cargando…

Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen

Development of a vaccine against HIV remains a major target goal in the field. The recent success of mRNA vaccines against the coronavirus SARS-CoV-2 is pointing out a new era of vaccine designs against pathogens. Here, we have generated two types of mRNA vaccine candidates against HIV-1; one based...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gómez, Carmen Elena, Perdiguero, Beatriz, Usero, Lorena, Marcos-Villar, Laura, Miralles, Laia, Leal, Lorna, Sorzano, Carlos Óscar S., Sánchez-Corzo, Cristina, Plana, Montserrat, García, Felipe, Esteban, Mariano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473054/ https://www.ncbi.nlm.nih.gov/pubmed/34579196 http://dx.doi.org/10.3390/vaccines9090959

Ejemplares similares

The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses
por: Usero, Lorena, et al.
Publicado: (2023)

Induction of Broad and Polyfunctional HIV-1-Specific T Cell Responses by the Multiepitopic Protein TMEP-B Vectored by MVA Virus
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B
por: Perdiguero, Beatriz, et al.
Publicado: (2018)

A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses
por: Falqui, Michela, et al.
Publicado: (2023)

In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?
por: Esteban, Ignasi, et al.
Publicado: (2021)

The Evolution of Poxvirus Vaccines
por: Sánchez-Sampedro, Lucas, et al.
Publicado: (2015)

Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases
por: Perdiguero, Beatriz, et al.
Publicado: (2023)

Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization
por: C. Guardo, Alberto, et al.
Publicado: (2017)

Comparison of Safety and Vector-Specific Immune Responses in Healthy and HIV-Infected Populations Vaccinated with MVA-B
por: Couto, Elvira, et al.
Publicado: (2019)

Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization
por: Guardo, Alberto C., et al.
Publicado: (2018)

Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways
por: Gómez, Carmen Elena, et al.
Publicado: (2017)

HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
por: Capucci, Silvia, et al.
Publicado: (2017)

Correction: HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers
por: Capucci, Silvia, et al.
Publicado: (2023)

Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens
por: Perdiguero, Beatriz, et al.
Publicado: (2012)

An MVA Vector Expressing HIV-1 Envelope under the Control of a Potent Vaccinia Virus Promoter as a Promising Strategy in HIV/AIDS Vaccine Design
por: Pérez, Patricia, et al.
Publicado: (2019)

Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines
por: Meseda, Clement A., et al.
Publicado: (2016)

Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2
por: Mooij, Petra, et al.
Publicado: (2022)

Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions
por: García-Arriaza, Juan, et al.
Publicado: (2010)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
por: Pérez, Patricia, et al.
Publicado: (2020)

Optimized Hepatitis C Virus (HCV) E2 Glycoproteins and their Immunogenicity in Combination with MVA-HCV
por: Marín, María Q., et al.
Publicado: (2020)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART
por: Gómez, Carmen Elena, et al.
Publicado: (2015)

Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles
por: Bridge, Simon H, et al.
Publicado: (2011)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
por: Beavis, Ashley C., et al.
Publicado: (2023)

Improving the MVA Vaccine Potential by Deleting the Viral Gene Coding for the IL-18 Binding Protein
por: Falivene, Juliana, et al.
Publicado: (2012)

High Quality Long-Term CD4(+) and CD8(+) Effector Memory Populations Stimulated by DNA-LACK/MVA-LACK Regimen in Leishmania major BALB/c Model of Infection
por: Sánchez-Sampedro, Lucas, et al.
Publicado: (2012)

Tauopathy Analysis in P301S Mouse Model of Alzheimer Disease Immunized with DNA and MVA Poxvirus-Based Vaccines Expressing Human Full-Length 4R2N or 3RC Tau Proteins
por: García-Arriaza, Juan, et al.
Publicado: (2020)

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways
por: García-Arriaza, Juan, et al.
Publicado: (2013)

The combined vaccination protocol of DNA/MVA expressing Zika virus structural proteins as efficient inducer of T and B cell immune responses
por: Pérez, Patricia, et al.
Publicado: (2021)

Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression
por: Q. Marín, María, et al.
Publicado: (2018)

Alphavirus Replicon DNA Expressing HIV Antigens Is an Excellent Prime for Boosting with Recombinant Modified Vaccinia Ankara (MVA) or with HIV gp140 Protein Antigen
por: Knudsen, Maria L., et al.
Publicado: (2015)

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

Dendritic Cells Exposed to MVA-Based HIV-1 Vaccine Induce Highly Functional HIV-1-Specific CD8(+) T Cell Responses in HIV-1-Infected Individuals
por: Climent, Núria, et al.
Publicado: (2011)

A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses
por: García-Arriaza, Juan, et al.
Publicado: (2011)

DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost
por: Öhlund, Pontus, et al.
Publicado: (2018)

Chicken Embryonic-Stem Cells Are Permissive to Poxvirus Recombinant Vaccine Vectors
por: Giotis, Efstathios S., et al.
Publicado: (2019)

Poxvirus tropism
por: McFadden, Grant
Publicado: (2005)

Poxvirus Recombination
por: Evans, David Hugh
Publicado: (2022)

Zoonotic poxviruses()
por: Essbauer, Sandra, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9t4nbgt98dvtso7fdqkbfe3q8u